6VI4 image
Deposition Date 2020-01-11
Release Date 2020-03-18
Last Version Date 2024-11-13
Entry Detail
PDB ID:
6VI4
Title:
Nanobody-Enabled Monitoring of Kappa Opioid Receptor States
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Lama glama (Taxon ID: 9844)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.30 Å
R-Value Free:
0.27
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
P 21 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Kappa opioid receptor
Gene (Uniprot):OPRK1
Mutations:I135L
Chain IDs:A, B
Chain Length:307
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Nanobody 6
Chain IDs:C, D
Chain Length:133
Number of Molecules:2
Biological Source:Lama glama
Primary Citation
Nanobody-enabled monitoring of kappa opioid receptor states.
Nat Commun 11 1145 1145 (2020)
PMID: 32123179 DOI: 10.1038/s41467-020-14889-7

Abstact

Recent studies show that GPCRs rapidly interconvert between multiple states although our ability to interrogate, monitor and visualize them is limited by a relative lack of suitable tools. We previously reported two nanobodies (Nb39 and Nb6) that stabilize distinct ligand- and efficacy-delimited conformations of the kappa opioid receptor. Here, we demonstrate via X-ray crystallography a nanobody-targeted allosteric binding site by which Nb6 stabilizes a ligand-dependent inactive state. As Nb39 stabilizes an active-like state, we show how these two state-dependent nanobodies can provide real-time reporting of ligand stabilized states in cells in situ. Significantly, we demonstrate that chimeric GPCRs can be created with engineered nanobody binding sites to report ligand-stabilized states. Our results provide both insights regarding potential mechanisms for allosterically modulating KOR with nanobodies and a tool for reporting the real-time, in situ dynamic range of GPCR activity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures